ConvaTec
Global medical products and technologies company focused on chronic-care and specialist medical products.
Last updated October 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ConvaTec is a United Kingdom-based medical products and technologies company serving patients, clinicians, hospitals and community-care providers in more than 100 countries. Its principal activities are advanced wound care, ostomy care, continence care and infusion care. The company’s portfolio is concentrated in products used in the management of chronic or recurring conditions, including wound-treatment products, ostomy systems, urinary catheters and insulin-infusion equipment. The business originated in 1978 as a division of E.R. Squibb & Sons. It later became an independent medical-products company and, in 2008, was acquired by Nordic Capital and Avista Capital Partners. That transaction was combined with the integration of Unomedical, a Danish manufacturer of single-use medical devices. To address European Commission competition requirements, ConvaTec sold Unomedical’s wound-care and ophthalmic businesses. ConvaTec expanded through specialist acquisitions. In 2012 it acquired 180 Medical, a United States catheter manufacturer, strengthening its continence-care activities. In 2017 it acquired Dutch company Eurotec Beheer, which was associated with ostomy products. In 2022 it purchased Triad Life Sciences, a United States wound-care company, for $125 million; the acquired operation was subsequently renamed Convatec Advanced Tissue Technology. In 2023 it acquired the anti-infective nitric-oxide technology platform of 30 Technology Ltd. The company entered the public markets on the London Stock Exchange in October 2016 in an offering that valued it at approximately £4.4 billion and was described as the largest London Stock Exchange initial public offering of that year. It later became a constituent of the FTSE 100 Index. Nordic Capital completed the disposal of its remaining ConvaTec stake in 2018. Performance after the flotation was affected by successive profit warnings, stagnant revenue growth and criticism that investment had been insufficient before the initial public offering. Several senior executives departed during the late 2010s, while reports in 2019 said that potential buyers were examining the company after a decline in its share price. ConvaTec subsequently adopted a strategy centered on chronic-care markets and recurring-use products, while reducing exposure to lower-margin product categories. During the early 2020s it divested or withdrew from selected skincare and lower-margin hospital-care activities. By 2023, the company said that the great majority of its revenue came from products used in chronic conditions, including insulin pumps and colostomy bags. These products generally support continuing treatment and can produce relatively predictable demand. ConvaTec also increased its emphasis on innovation, setting a goal that 30 percent of sales would come from products less than five years old by 2025. Its research-and-development spending rose from 2.7 percent of sales in 2018 to 4.6 percent in 2023, according to the referenced account. ConvaTec remains an international specialist healthcare supplier rather than a general consumer housewares brand. Its business model combines branded medical products, clinical technologies and related support across hospital, home-care and community-care settings. The company has also faced scrutiny over its continuing commercial presence in Russia after the invasion of Ukraine. It suspended its Russian sales team and closed its Belarus manufacturing site during 2022, but was later criticized by organizations tracking companies that had not fully exited Russia.
History
ConvaTec began in 1978 as a division of E.R. Squibb & Sons. From its origins within a major pharmaceutical group, it developed into a specialist supplier of medical consumables and technologies, particularly in areas where patients require repeated or long-term treatment. Its principal fields became advanced wound care, ostomy care, continence care and infusion care. A major ownership change occurred in 2008, when Nordic Capital and Avista Capital Partners acquired the business. During the same year, ConvaTec was integrated with Unomedical, a Denmark-based manufacturer of single-use medical devices. The combined transaction required portfolio changes to satisfy European Commission competition requirements, and the Unomedical wound-care and ophthalmic businesses were sold. ConvaTec used acquisitions to broaden its specialist capabilities. In 2012 it purchased 180 Medical, a United States catheter manufacturer, for $321 million. The deal strengthened its continence-care platform and expanded its presence in the home medical-supply market. In 2015 the company was involved in a patent dispute that reached the Court of Appeal. The court addressed how a numerical range in a patent should be interpreted and found that an attempt to work around the patent using a 0.9% formulation did not succeed. The company went public on the London Stock Exchange in October 2016. The flotation valued ConvaTec at roughly £4.4 billion and was the largest London Stock Exchange initial public offering of that year according to the cited account. It became a FTSE 100 constituent two months later. In January 2017 it bought Eurotec Beheer of the Netherlands for £21.3 million. Nordic Capital subsequently sold its entire remaining interest in ConvaTec by May 2018. The years after the flotation were difficult. ConvaTec was associated with repeated profit warnings, limited revenue momentum and concerns that investment had been constrained before the IPO. The resulting pressure contributed to the departure of several executives during the late 2010s. In early 2019, reports indicated that investors were examining a possible acquisition after the company’s share-price decline; EQT was named as one possible participant, although no completed takeover followed in the cited material. ConvaTec then reshaped its strategy around chronic diseases and products with recurring demand. It reduced exposure to lower-margin lines, including parts of skincare and hospital care, while prioritizing products such as ostomy bags, catheters and insulin-infusion equipment. By 2023, the cited account said that 97% of revenue came from products associated with chronic conditions. The company also increased research-and-development intensity, with R&D spending rising from 2.7% of sales in 2018 to 4.6% in 2023. It set a target for products less than five years old to account for 30% of sales by 2025. The acquisition program continued in the 2020s. In early 2022 ConvaTec acquired Triad Life Sciences, a United States wound-care company, for $125 million and renamed the business Convatec Advanced Tissue Technology. In 2023 it bought the anti-infective nitric-oxide technology platform of 30 Technology Ltd. The company also faced geopolitical and reputational issues connected with Russia. It closed a manufacturing facility in Belarus and suspended its Russian sales team in 2022, but campaign groups continued to criticize its ongoing Russian-market activity in 2023. In August 2024 ConvaTec expressed concern that United Kingdom regulatory approval procedures could discourage investment and innovation. Its current identity is that of an international chronic-care and medical-technology company rather than a general consumer-products business.
- 2023
Nitric-oxide technology acquisition
[1]ConvaTec acquired the anti-infective nitric-oxide technology platform of 30 Technology Ltd.
- 2022
Triad Life Sciences acquisition
[1]The company acquired Triad Life Sciences and rebranded the business as Convatec Advanced Tissue Technology.
- 2017
Acquisition of Eurotec Beheer
[1]ConvaTec acquired the Dutch company Eurotec Beheer.
- 2016
London Stock Exchange initial public offering
[1]ConvaTec completed an IPO that valued the company at approximately £4.4 billion.
- 2016
Added to the FTSE 100
[1]The company became a constituent of the FTSE 100 Index.
- 2012
Acquisition of 180 Medical
[1]ConvaTec acquired United States catheter manufacturer 180 Medical.
- 2008
Acquisition by Nordic Capital and Avista Capital Partners
[1]The company was acquired by Nordic Capital and Avista Capital Partners and integrated with Unomedical.
- 1978
Business established within E.R. Squibb & Sons
[1]ConvaTec was established as a division of E.R. Squibb & Sons.
Products and positioning
A specialist medical-technology company positioned around chronic-care management, recurring-use medical products, clinical outcomes and innovation in wound, ostomy, continence and infusion care.
Wound-care products
Advanced wound care
ConvaTec’s advanced wound-care portfolio is designed for the management of chronic, complex and acute wounds. It includes products and technologies intended to protect wounds, manage exudate, support healing and address infection-related risks. The category is central to the company’s clinical positioning and includes capabilities added through the Triad Life Sciences acquisition and the later nitric-oxide technology transaction.
Ostomy systems
Ostomy care
Ostomy-care products support people living with a surgically created stoma, including colostomies and other forms of ostomy. The range includes collection bags, skin-protection products, seals, accessories and related care solutions. These products are typically used continuously, making ostomy care one of ConvaTec’s core chronic-care businesses.
Catheters and continence products
Continence care
ConvaTec’s continence-care activities include urinary catheters and associated products used by patients who require intermittent or ongoing assistance with bladder management. The acquisition of 180 Medical expanded the company’s United States catheter business and reinforced its focus on home-based and recurring medical care.
Infusion and insulin-delivery products
Infusion care
Infusion-care products support the delivery of medicines and other therapies through infusion systems. The company’s chronic-care emphasis includes insulin-infusion products and related equipment, which are used in ongoing treatment and contribute to ConvaTec’s recurring-use product mix.
Advanced tissue and wound-care technology · 2022
Convatec Advanced Tissue Technology
Convatec Advanced Tissue Technology is the name applied to the former Triad Life Sciences business after ConvaTec acquired it in 2022. The unit extends the company’s wound-care technology capabilities and provides a platform for products serving complex tissue and wound-management needs.
Controversies
2026
Inventor David Parsons sues Convatec for up to £366m over Aquacel patent profits
Analytical chemist Dr David Parsons, who worked for FTSE100-listed Convatec Ltd from 1991 until 2023, is suing the medical products company at the UK High Court for compensation of up to £366m under Section 40 of the Patents Act 1977, claiming that patents bearing his name - used in ConvaTec's Aquacel antimicrobial wound dressings - created an 'outstanding' benefit for his employer. Convatec is fighting the claim, arguing compensation is due only for exceptional individual inventions rather than patents considered collectively; the case reached the Court of Appeal this week over the issues to be determined, judgment is likely to be reserved, and a six-week High Court trial is set for 2028.
2023
Criticism over continued Russian-market activity
ConvaTec was included in the Leave Russia project, which tracks companies that continued operating in Russia. Critics argued that continued sales activity indirectly supported the Russian economy and government during the war in Ukraine. The company had suspended its Russian sales team and closed its Belarus manufacturing facility in 2022, but criticism continued over its broader Russian presence.
Brand decisions
2024
Regulatory-approval policy interventionOtherBackground
ConvaTec assessed the United Kingdom’s regulatory environment for medical products and technologies.
Action taken
The company publicly warned that the regulatory approval process could deter future innovation and investment.
Aftermath
The statement positioned ConvaTec as an industry voice on the effect of regulation on medical-technology development.
2023
Acquisition of 30 Technology’s nitric-oxide platformM&ABackground
ConvaTec continued to invest in technologies connected with wound care and infection management.
Action taken
The company acquired the anti-infective nitric-oxide technology platform of 30 Technology Ltd.
Aftermath
The transaction added a technology platform to ConvaTec’s advanced wound-care and anti-infective capabilities.
2022
Acquisition of Triad Life SciencesM&ABackground
ConvaTec sought to expand its advanced wound-care and tissue-technology capabilities.
Action taken
The company acquired Triad Life Sciences and renamed the business Convatec Advanced Tissue Technology.
Aftermath
The acquisition broadened ConvaTec’s wound-care technology platform.
Acquisition consideration. $125 million (Early 2022)
2022
Reduction of activity in Belarus and RussiaStrategyBackground
Russia’s invasion of Ukraine created operational, reputational and geopolitical risks for companies active in the region.
Action taken
ConvaTec closed its manufacturing facility in Belarus and suspended its Russian sales team.
Aftermath
The company nevertheless continued to face criticism over remaining Russian-market activity.
2019
Shift toward chronic-care marketsStrategyBackground
Following profit warnings, weak growth and concerns about the company’s post-IPO performance, ConvaTec reassessed its portfolio and growth model.
Action taken
The company prioritized chronic-care products with recurring demand and reduced its exposure to lower-margin product lines.
Aftermath
The strategy supported increased emphasis on ostomy, continence, infusion and advanced wound-care products, alongside higher research-and-development investment.
2016
Public listing on the London Stock ExchangeOtherBackground
After ownership by private-equity investors, ConvaTec pursued a public-market listing.
Action taken
The company completed an initial public offering on the London Stock Exchange.
Aftermath
The flotation valued ConvaTec at approximately £4.4 billion, and the company later joined the FTSE 100.
IPO valuation. Approximately £4.4 billion (October 2016)
Recent events
- Unconfirmed
Inventor David Parsons sues Convatec for up to £366m over Aquacel patent profits[3]
Reported:
Analytical chemist Dr David Parsons, who worked for FTSE100-listed Convatec Ltd from 1991 until 2023, is suing the medical products company at the UK High Court for compensation of up to £366m under Section 40 of the Patents Act 1977, claiming that patents bearing his name - used in ConvaTec's Aquacel antimicrobial wound dressings - created an 'outstanding' benefit for his employer. Convatec is fighting the claim, arguing compensation is due only for exceptional individual inventions rather than patents considered collectively; the case reached the Court of Appeal this week over the issues to be determined, judgment is likely to be reserved, and a six-week High Court trial is set for 2028.
Medline announces acquisition of SensiCare and Aloe Vesta product lines[4]
Reported:
Medline announced the acquisition of the SensiCare and Aloe Vesta skin care product lines from ConvaTec for $29 million. The sale was expected to close in the third quarter of 2020.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/convatec · Editorial policy · How profiles are compiled